Duke Cancer Institute

Running trials

• Recruiting

  Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

  NCT06983691· Source

• Not yet recruiting

  A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

  NCT07650357· Phase 1· Source

• Recruiting

  A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07325136· Phase 1/2· Source

• Recruiting

  Improving Outcomes in Early Menopause After Cancer

  NCT06982677· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Source

• Recruiting

  ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  NCT07007559· Phase 2· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

  NCT07196644· Phase 2· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  NCT07206225· Phase 1· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Source

• Recruiting

  Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

  NCT06774027· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· Source

• Recruiting

  Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

  NCT07049926· Phase 1/2· Source

• Recruiting

  Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors

  NCT06371768· Source

• Recruiting

  Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06995677· Phase 2· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Source

• Recruiting

  Safety of HRX215 in Patients After Minor and Major Liver Resection

  NCT06638502· Phase 1/2· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Source

• Not yet recruiting

  BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

  NCT06620029· Phase 1/2· Source

• Recruiting

  A Study of PHST001 in Advanced Solid Tumors

  NCT06840886· Phase 1· Source

• Active, not recruiting

  Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

  NCT06840483· Phase 2· Source

• Recruiting

  A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  NCT06778863· Phase 1· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  NCT06646276· Phase 3· Source

• Active, not recruiting

  Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

  NCT06619236· Phase 3· Source

• Recruiting

  A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  NCT06706076· Phase 1/2· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Source

• Active, not recruiting

  A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

  NCT06365853· Phase 2· Source

• Active, not recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  NCT06459180· Phase 3· Source

• Recruiting

  A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

  NCT06515613· Phase 1· Source

• Recruiting

  Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

  NCT05932199· Phase 1/2· Source

• Active, not recruiting

  A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

  NCT06307431· Phase 2· Source

• Active, not recruiting

  A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

  NCT06305767· Phase 1/2· Source

• Recruiting

  A Phase 1/1b Study of IAM1363 in HER2 Cancers

  NCT06253871· Phase 1· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Source

• Active, not recruiting

  Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

  NCT06107413· Phase 2· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

  NCT05968326· Phase 2· Source

• Recruiting

  A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT06067841· Phase 1· Source

• Active, not recruiting

  A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

  NCT05933577· Phase 3· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

  NCT05845814· Phase 1/2· Source

• Recruiting

  SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  NCT05303519· Phase 3· Source

• Active, not recruiting

  Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

  NCT05683691· Source

• Active, not recruiting

  Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  NCT05445778· Phase 3· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Source

• Active, not recruiting

  Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

  NCT05501054· Phase 1/2· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Source

• Active, not recruiting

  Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

  NCT05544552· Phase 1/2· Source

• Active, not recruiting

  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

  NCT05585320· Phase 1/2· Source

Showing 50 of 74.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer9 recruiting
• Colorectal cancer6 recruiting
• Ovarian cancer6 recruiting
• Endometrial cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Triple-negative breast cancer5 recruiting
• Bladder cancer4 recruiting
• Gastric and oesophageal cancer3 recruiting
• Pancreatic cancer3 recruiting
• Childhood cancers2 recruiting
• Head and neck cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Glioblastoma1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting

Researchers

• ASAngeles Alvarez Secord

Closed trials

• Completed

  A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

  NCT06399757· Phase 1· Source

• Terminated

  A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

  NCT06194877· Phase 1· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Source

• Completed

  Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

  NCT06036836· Phase 2· Source

• Completed

  Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)

  NCT05686122· Source

• Completed

  HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

  NCT05902494· Source

• Terminated

  Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

  NCT05617313· Phase 2· Source

• Completed

  Adolescents and Young Adults (AYAs) With Advanced Cancer

  NCT05593016· Source

• Completed

  DBT for Metastatic Lung Cancer

  NCT04973436· Source

• Recruiting

  MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

  NCT05076760· Phase 1· Source

• Terminated

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Phase 2· Source

• Terminated

  A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT05169684· Phase 2· Source

• Completed

  A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

  NCT05039177· Phase 1/2· Source

• Completed

  An mHealth Symptom Management Intervention for Colorectal Cancer Patients (mCOPE)

  NCT04763174· Source

• Completed

  Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

  NCT05075603· Phase 1· Source

• Completed

  Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

  NCT04700072· Phase 1/2· Source

• Terminated

  CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

  NCT04698187· Phase 2· Source

• Terminated

  CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

  NCT04695977· Phase 2/3· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Source

• Completed

  Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

  NCT04305054· Phase 1/2· Source

• Completed

  Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

  NCT04305041· Phase 1/2· Source

• Completed

  Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

  NCT04303169· Phase 1/2· Source

• Terminated

  Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

  NCT04305444· Phase 2· Source

• Completed

  Symptom Management for YA Cancer Survivors

  NCT04035447· Source

• Completed

  A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

  NCT03752398· Phase 1· Source

• Completed

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· Phase 3· Source

• Completed

  Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

  NCT02655601· Phase 1/2· Source

• Completed

  CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

  NCT03425279· Phase 1/2· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Source

Trial sites

• Duke Cancer Institute Cary3 trials
• Duke Cancer Institute68 trials
• Duke Cancer Institute (Adults and Pediatrics)1 trial
• Duke Cancer Institute (DCI) - Duke Cancer Center1 trial
• Duke Cancer Institute /ID# 2472361 trial
• Duke Cancer Institute /ID# 2572361 trial
• Duke Cancer Institute /ID# 2693421 trial
• Duke Cancer Institute /ID# 2695571 trial
• Duke Cancer Institute /ID# 2756041 trial
• Duke Cancer Institute /ID# 2762671 trial
• Duke Cancer Institute - Sarcoma Research1 trial
• Duke Cancer Institute - School of Medicine1 trial
• Duke Cancer Institute (Site 0038)1 trial
• Duke Cancer Institute (Site 0042)1 trial
• Duke Cancer Institute (Site 0096)1 trial
• Duke Cancer Institute (Site 0106)1 trial
• Duke Cancer Institute (Site 0107)1 trial
• Duke Cancer Institute (Site 0641)1 trial
• Duke Cancer Institute (Site 1005)1 trial
• Duke Cancer Institute (Site 1015)1 trial
• Duke Cancer Institute (Site 1541)1 trial
• Duke Cancer Institute (Site 1911)1 trial
• Duke Cancer Institute (Site 2005)1 trial
• Duke Cancer Institute (Site 3005)1 trial
• Duke Cancer Institute (Site 3015)1 trial
• Duke Cancer Institute (Site 3027)1 trial
• Duke Cancer Institute (Site 4005)1 trial
• Duke Cancer Institute (Site 4120)2 trials
• Duke Cancer Institute (Site 5015)1 trial
• Duke Cancer Institute (Site 6049)1 trial
• Duke Institute of Cancer/ Duke University1 trial
• Duke University Cancer Institute3 trials
• Duke University School of Medicine, Duke Cancer Institute1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer104 works · 6 trials
• Metastatic breast cancer24 works · 8 trials
• Head and neck cancer13 works · 6 trials
• Chronic lymphocytic leukaemia8 works · 1 trial